In January, Health Canada made the process of accessing legal psilocybin-psychotherapy for mental health conditions easier for patients. Psilocybin is the active compound found in magic mushrooms.
Thomas Hartle, a 54-year-old suffering from terminal colon cancer, is one of the patients who has benefited from this. Hartle undergoes psilocybin treatment for the management of his end-of-life anxiety, which was brought on by his terminal illness diagnosis. He is one of the few individuals in Canada who have received legal psychedelic therapy since Health Canada made it possible to do so by restoring its Special Access Program.
The country’s Special Access Program, which allowed physicians to request for access to restricted medications that weren’t authorized for commercial sale, was abolished in 2013. Before its restoration, individuals could only access psychedelic-assisted psychotherapy via medical exemptions and clinical trials. Now licensed professionals can file for approval on behalf of patients with mental illnesses such as anxiety, depression and PTSD, especially for those who haven’t benefited from conventional therapies.
Health Canada recently revealed that since the program’s resumption, it had received 15 requests to administer MDMA or psilocybin. This comes as Mindspace prepares to launch a new healthcare facility in Montreal, Quebec. The clinic, which will be called Mindspace by Numinus, will be the first clinic in the province to use psilocybin to treat depression legally.
In a recent interview, Dr. Andrew Bui-Nguyen, a clinic physician and health-care provider, stated that it was an honor to be able to help individuals with their psychological distress and provide something different from conventional therapies. Bui-Nguyen revealed that the clinic had obtained approval from Health Canada on May 5, 2022, enabling clinic physicians to provide care to patients who had tried to manage their depression using conventional treatments without success.
Bui-Nguyen also stated that there was a thorough screening process in place for patients who were eligible for the treatment, explaining that they examined the patient’s diagnosis as well as their medical history, what treatments they had tried and whether there existed a risk of addiction. He also explained that psychedelic-assisted therapy required that a number of therapy sessions be conducted, both before and after each patient had received the drug. During their psychedelic treatments, patients will have psilocybin administered to them while under supervision by a pair of psychotherapists.
Many believe that psychedelics may significantly improve the clinical care for various mental illnesses, with Payton Nyquvest, CEO of Mindspace by Numinus, noting that he hopes psilocybin therapy will become more accessible to all.
The options for patients in Canada in need of novel treatments for mental disorders are now broadening beyond the ketamine clinics operated by companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to therapies leveraging psilocybin. As more such treatments become available, patients who hadn’t benefited from the conventional treatments will have better outcomes from the psychedelic treatments.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
